VAERS Explorer
Back to explore

Report #2890094

Received Mar 20, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Unknown
Age
Age unknown
State
CO
Recovered
Unknown
Vaccinated
Onset
Days to onset
Hospital days

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
TYPTYPHOID LIVE ORAL TY21A (VIVOTIF)BERNA BIOTECH, LTD.3Unknown

Symptoms (1)

Product dose omission issue

Symptom narrative

The patient took the three doses of Vivotif, and missed the fourth dose; Case reference number US-BN-2024-001983 is a spontaneous case initially received from a pharmacist via Communications (reference number: USBAV23-1245) on 03-Jun-2024 and concerns a patient of unspecified demographics. The patient's relevant medical history and concomitant medication details were not provided. On unspecified dates, the patient took three doses of Vivotif (batch number: unknown), at unknown doses, or routes of administration, for an unknown indication. On an unspecified date, as reported it was one week since last dose of Vivotif, the patient missed fourth dose of Vivotif (explicitly coded as 'missed dose'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. Additional information received from Bavarian Nordic on 04-Jun-2024 included reporter name updated. Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20240603-0a87f5 to US-BAVARIAN NORDIC A/S-US-BN-2024-001983, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: A patient of unspecified demographics missed fourth dose of Vivotif. Product dose omission issue is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to Vivotif. The patient's relevant medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A patient of unspecified demographics missed fourth dose of Vivotif. Product dose omission issue is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to Vivotif. The patient's relevant medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.

Medical history

Comments: None.